BR112014001573B8 - MULTIVALENT ANTIGEN FV MOLECULE - Google Patents

MULTIVALENT ANTIGEN FV MOLECULE

Info

Publication number
BR112014001573B8
BR112014001573B8 BR112014001573A BR112014001573A BR112014001573B8 BR 112014001573 B8 BR112014001573 B8 BR 112014001573B8 BR 112014001573 A BR112014001573 A BR 112014001573A BR 112014001573 A BR112014001573 A BR 112014001573A BR 112014001573 B8 BR112014001573 B8 BR 112014001573B8
Authority
BR
Brazil
Prior art keywords
antigen
binding molecule
polypeptide
multivalent antigen
molecule
Prior art date
Application number
BR112014001573A
Other languages
Portuguese (pt)
Other versions
BR112014001573B1 (en
BR112014001573A2 (en
Inventor
Little Melvyn
Le Gall Fabrice
Original Assignee
Affimed Therapeutics Ag
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics Ag, Affimed Gmbh filed Critical Affimed Therapeutics Ag
Publication of BR112014001573A2 publication Critical patent/BR112014001573A2/en
Publication of BR112014001573B1 publication Critical patent/BR112014001573B1/en
Publication of BR112014001573B8 publication Critical patent/BR112014001573B8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

MOLÉCULA FV DE LIGAÇÃO AO ANTÍGENO MULTIVALENTE. Em um aspecto, a presente invenção refere-se a uma molécula de ligação ao antígeno específica para albumina e CD3, compreendendo duas cadeias polipeptídicas, cada cadeia polipeptídica possuindo pelo menos quatro domínios variáveis em uma orientação que impede a formação de Fv e as duas cadeias polipeptídicas são dimerizadas uma com a outra, assim formando uma molécula de ligação ao antígeno multivalente. Em cada uma das duas cadeias polipeptídicas, os quatro domínios variáveis são dispostos na ordem VLA-VHB-VLB-VHA a partir do N-terminal para o C-terminal do polipeptídeo. As composições da molécula de ligação ao antígeno e os métodos de utilização da molécula de ligação ao antígeno ou as suas composições para o tratamento de várias doenças também são aqui fornecidos.MULTIVALENT ANTIGEN-BINDING MOLECULE FV. In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3, comprising two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation that prevents Fv formation and the two chains polypeptides are dimerized with one another, thus forming a multivalent antigen-binding molecule. In each of the two polypeptide chains, the four variable domains are arranged in the order VLA-HBV-VLB-HAV from the N-terminus to the C-terminus of the polypeptide. Compositions of the antigen-binding molecule and methods of using the antigen-binding molecule or compositions thereof for treating various diseases are also provided herein.

BR112014001573A 2011-07-22 2011-07-22 MULTIVALENT ANTIGEN FV MOLECULE BR112014001573B8 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/062673 WO2013013700A1 (en) 2011-07-22 2011-07-22 Multivalent antigen-binding fv molecule

Publications (3)

Publication Number Publication Date
BR112014001573A2 BR112014001573A2 (en) 2017-02-21
BR112014001573B1 BR112014001573B1 (en) 2022-08-30
BR112014001573B8 true BR112014001573B8 (en) 2022-11-08

Family

ID=44719851

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001573A BR112014001573B8 (en) 2011-07-22 2011-07-22 MULTIVALENT ANTIGEN FV MOLECULE

Country Status (8)

Country Link
JP (1) JP5938473B2 (en)
CN (1) CN103687879B (en)
AU (1) AU2011373925B2 (en)
BR (1) BR112014001573B8 (en)
CA (1) CA2842649C (en)
MX (1) MX347829B (en)
RU (1) RU2613368C2 (en)
WO (1) WO2013013700A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009586A0 (en) 2014-05-29 2016-11-30 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
BR112016030740A2 (en) 2014-07-01 2018-02-20 Pfizer Inc. bispecific heterodimeric bodies and their uses
AU2015380455A1 (en) 2015-01-26 2017-08-03 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
BR112017025479A2 (en) 2015-05-29 2018-08-07 Amphivena Therapeutics Inc methods for using bispecific cd33 and cd3 binding proteins
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
JO3736B1 (en) 2015-07-30 2021-01-31 Macrogenics Inc PD-1-Binding Molecules and Methods of Use Thereof
MX2018007089A (en) 2015-12-14 2019-01-30 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof.
AR108034A1 (en) 2016-02-17 2018-07-11 Macrogenics Inc MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME
TWI781098B (en) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
EP3579848A4 (en) 2017-02-08 2021-03-03 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
DK3582806T3 (en) 2017-02-20 2023-09-11 Dragonfly Therapeutics Inc PROTEINS THAT BIND HER2, NKG2D AND CD16
AU2018228719B2 (en) * 2017-02-28 2023-03-30 Affimed Gmbh Tandem diabody for CD16A-directed NK-cell engagement
BR112020007384A2 (en) 2017-10-26 2020-09-29 Saint-Gobain Glass France add-on piece having an integrated camera module
EP3724231A4 (en) 2017-12-12 2021-08-11 MacroGenics, Inc. Bispecific cd 16-binding molecules and their use in the treatment of disease
BR112020016190A2 (en) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. ANTIBODY VARIABLE DOMAINS DIRECTING THE NKG2D RECEIVER
AU2019222666A1 (en) 2018-02-15 2020-09-03 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
EP3802617A4 (en) * 2018-06-07 2022-04-27 Cullinan Oncology, Inc. Multi-specific binding proteins and methods of use thereof
RU2738802C1 (en) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Complementarity-determining regions for binding cd3 and a bispecific antigen-binding molecule containing thereof
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
DE19819846B4 (en) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
ATE512989T1 (en) * 2002-04-15 2011-07-15 Chugai Pharmaceutical Co Ltd METHOD FOR PRODUCING SCDB LIBRARIES
ES2559763T3 (en) 2002-09-10 2016-02-15 Affimed Gmbh CD3 specific human antibody with immunosuppressive properties
JPWO2005056605A1 (en) * 2003-12-12 2007-12-06 中外製薬株式会社 Modified antibody that recognizes a trimer or higher receptor
WO2006106903A1 (en) * 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
EP2412808B1 (en) * 2009-03-25 2016-09-07 Tohoku University Lh-type bispecific antibody
ES2582001T3 (en) * 2010-02-25 2016-09-08 Affimed Gmbh Molecule that binds to antigen and uses thereof

Also Published As

Publication number Publication date
AU2011373925A1 (en) 2014-01-16
CA2842649C (en) 2020-01-21
MX2014000816A (en) 2014-07-09
RU2013157040A (en) 2015-08-27
BR112014001573B1 (en) 2022-08-30
MX347829B (en) 2017-05-15
RU2613368C2 (en) 2017-03-16
AU2011373925B2 (en) 2016-04-28
CN103687879B (en) 2016-05-04
CA2842649A1 (en) 2013-01-31
CN103687879A (en) 2014-03-26
JP5938473B2 (en) 2016-06-22
BR112014001573A2 (en) 2017-02-21
WO2013013700A1 (en) 2013-01-31
JP2014527515A (en) 2014-10-16

Similar Documents

Publication Publication Date Title
BR112014001573B8 (en) MULTIVALENT ANTIGEN FV MOLECULE
CL2018001827A1 (en) Antibody type binding protein with dual variable region comprising four polypeptide chains that form four antigen binding sites; nucleic acid molecule that encodes it; expression vector; cell; elaboration method; and pharmaceutical composition comprising it (divisional application 201302763)
CY1121392T1 (en) COMBINATION MOLECULES AGAINST ALPHA-SYNUCLEIN
EA201400568A1 (en) ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS
AR077088A1 (en) BISPECIFIC PROTEINS OF ANTIGEN UNION
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
PE20150023A1 (en) ST2 ANTIGEN BINDING PROTEINS
BR112016011025A8 (en) humanized anti-kallikrein-2 antibody.
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
CO2018004094A2 (en) Cd3 binding polypeptides
BR112018001530A2 (en) bispecific antibody, polynucleotide, vector, host cell, methods for producing bispecific antibody and tumor cell growth inhibiting and pharmaceutical composition
BR112012006492A2 (en) multivalent antibody fusion protein, and albumin binding
MY191428A (en) Antigen binding molecules comprising a tnf family ligand trimer
BR112015000798A2 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EA201790757A1 (en) BONDING ANTIGEN CD27L PROTEINS
BR112014025830A8 (en) CD3-BINDING POLYPEPTIDES
EA201290570A1 (en) CONSTRUCTIONS CONNECTING WITH RON AND METHODS OF THEIR USE
AR067199A1 (en) PROTEINS OF UNION TO ANTIGENS THAT JOIN PAR-2
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
EA201491571A1 (en) MODIFIED BISPECIFIC IgG4 ANTIBODIES WITH ASYMMETRIC SEQUENCE
RU2015152077A (en) TRIMER ANTIGEN-BINDING MOLECULES
EA201691782A1 (en) ANTIBODIES SPECIFIC TO THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1, AND THEIR APPLICATION
CL2021002792A1 (en) Monoclonal antibody that specifically binds to gitr
DOP2012000232A (en) SPECIFIC ANTIGEN BINDING PROTEINS FOR SERICO P AMILOID COMPONENT
EA201790816A1 (en) ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25D Requested change of name of applicant approved

Owner name: AFFIMED GMBH (DE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.